Literature DB >> 16809420

Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.

Volker Schmitz1, Esther Raskopf, Maria Angeles Gonzalez-Carmona, Annabelle Vogt, Christian Rabe, Ludger Leifeld, Miroslaw Kornek, Tilman Sauerbruch, Wolfgang H Caselmann.   

Abstract

BACKGROUND: The prognosis of patients with hepatocellular carcinoma (HCC) remains poor, and new alternative treatments are needed. AIMS: To comparatively test the angiostatic and antitumour effects of adenoviral gene transfer of angiostatin (PlgK1-4, amino acids 1-440) and full kringles 1-5 (PlgK1-5, amino acids 1-546) in a model of subcutaneously transferred HCC in mice.
METHODS: PlgK1-4 and PlgK1-5 were generated from human WtPlg cDNA and used for adenovirus construction. Vector function and angiostatic effects were confirmed in vitro and in vivo. Antitumoral efficacies of intratumoral vector injections were studied in a model of subcutaneously transferred HCC model.
RESULTS: Cell supernatants containing PlgK1-4 and PlgK1-5 reduced endothelial tube formation in vitro by about 30%, whereas WtPlg exerted no inhibitory effect. Endothelial cell infiltration in vivo was decreased by about 60%, but not in AdWtPlg-treated animals. Intratumoral treatment of subcutaneous HCC tumours inhibited growth by 40% for AdPlgK1-4 and 63% for AdPlgK1-5 in surviving mice 12 days after initiation of treatment, whereas treatment with AdWtPlg even led to accelerated growth. Although PlgK1-4 and PlgK1-5 have similar inhibitory effects on intratumoral microvessels, PlgK1-5 markedly improved the survival time compared with PlgK1-4.
CONCLUSION: PlgK1-5 and PlgK1-4 effectively inhibited HCC growth. As PlgK1-5 could also prolong the survival time, inducing complete tumour elimination in half of the AdPlgK1-5-treated mice, PlgK1-5 might be the most potential plasminogen fragment for treatment of experimental HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809420      PMCID: PMC1856779          DOI: 10.1136/gut.2005.088583

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Angiostatin and hepatocellular carcinoma.

Authors:  Gerald Soff
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

3.  Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells.

Authors:  Holly Anne Hanford; Christie A Wong; Hallie Kassan; Deborah L Cundiff; Navdeep Chandel; Suzanne Underwood; Christopher A Mitchell; Gerald A Soff
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

4.  Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.

Authors:  Guoquan Gao; Yan Li; Stephen Gee; Andrew Dudley; James Fant; Craig Crosson; Jian-xing Ma
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

5.  A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen.

Authors:  V Schmitz; L Wang; M Barajas; D Peng; J Prieto; C Qian
Journal:  Gene Ther       Date:  2002-12       Impact factor: 5.250

6.  Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector.

Authors:  H-I Ma; S-Z Lin; Y-H Chiang; J Li; S-L Chen; Y-P Tsao; X Xiao
Journal:  Gene Ther       Date:  2002-01       Impact factor: 5.250

Review 7.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

8.  Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene.

Authors:  Hiroki Ishikawa; Kazuhiko Nakao; Kojiro Matsumoto; Tatsuki Ichikawa; Keisuke Hamasaki; Keisuke Nakata; Katsumi Eguchi
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

9.  Multiple forms of angiostatin induce apoptosis in endothelial cells.

Authors:  R Lucas; L Holmgren; I Garcia; B Jimenez; S J Mandriota; F Borlat; B K Sim; Z Wu; G E Grau; Y Shing; G A Soff; N Bouck; M S Pepper
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

10.  Long-term expression of angiostatin suppresses metastatic liver cancer in mice.

Authors:  Ruian Xu; Xueying Sun; Lai-Yin Tse; Hua Li; Pui-Chung Chan; Sue Xu; Weidong Xiao; Hsiang-Fu Kung; Geoffrey W Krissansen; Sheung-Tat Fan
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

View more
  9 in total

1.  Plasminogen fragment K1-3 inhibits expression of adhesion molecules and experimental HCC recurrence in the liver.

Authors:  Esther Raskopf; Sevil Gerceker; Annabelle Vogt; Jens Standop; Tilman Sauerbruch; Volker Schmitz
Journal:  Int J Colorectal Dis       Date:  2009-01-27       Impact factor: 2.571

2.  Anti-tumoural effects of PlgK1-5 are directly linked to reduced ICAM expression, resulting in hepatoma cell apoptosis.

Authors:  Volker Schmitz; Tilman Sauerbruch; Esther Raskopf
Journal:  Int J Colorectal Dis       Date:  2012-03-28       Impact factor: 2.571

Review 3.  Hepatocellular carcinoma: insight from animal models.

Authors:  Yan Li; Zhao-You Tang; Jin-Xuan Hou
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-25       Impact factor: 46.802

4.  Adenoviral gene therapy in hepatocellular carcinoma: a review.

Authors:  Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  Hepatol Int       Date:  2012-04-25       Impact factor: 6.047

5.  Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Nitin Saini; Yogesh Kumar Chawla; Anuradha Chakraborti; Ajay Duseja; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Cell Biochem       Date:  2013-08-04       Impact factor: 3.396

6.  Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events.

Authors:  Jürgen Borlak; Prashant Singh; Giuseppe Gazzana
Journal:  BMC Genomics       Date:  2015-02-25       Impact factor: 3.969

7.  Anti‑angiogenesis gene therapy for hepatocellular carcinoma via systemic injection of mesenchymal stem cells engineered to secrete soluble Flt‑1.

Authors:  Guanglin Li; Fei Miao; Jinhai Zhu; Yanling Chen
Journal:  Mol Med Rep       Date:  2017-08-22       Impact factor: 2.952

8.  Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.

Authors:  Frank E Uschner; Ganesh Ranabhat; Steve S Choi; Michaela Granzow; Sabine Klein; Robert Schierwagen; Esther Raskopf; Sebastian Gautsch; Peter F M van der Ven; Dieter O Fürst; Christian P Strassburg; Tilman Sauerbruch; Anna Mae Diehl; Jonel Trebicka
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

9.  Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.

Authors:  Lea A Koch; Volker Schmitz; Christian P Strassburg; Esther Raskopf
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.